TVTX earnings analysis
What we found in TVTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Travere delivered strong Q2 revenue growth, with $169.584 million of revenue led by $141.078 million in FILSPARI sales, and moved to approximately $1.780 million of operating income. However, GAAP EPS was a $0.37 loss after a $40.008 million debt-inducement expense, while launch and pipeline investments accelerated. Liquidity was solid at $489.177 million of cash and marketable securities at June 30, although convertible debt increased to $602.781 million and the company paid Everest $112.5 million in July for civorebrutinib rights.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 48% on product-sales strength
- Q2 revenue rose $55.135 million year over year to $169.584 million, as total net product sales increased $66.510 million to $161.352 million. Gross margin was approximately 98.7%, with product cost of goods sold of just $2.174 million.
- FILSPARI was the core growth driver
- FILSPARI sales nearly doubled year over year, increasing $69.191 million to $141.078 million. The April 2026 FSGS approval expanded the addressable U.S. population by more than 30,000 individuals, alongside an estimated more than 70,000 addressable IgAN patients.
- Operations returned to modest profitability
- The company generated approximately $1.780 million of operating income in Q2, versus an operating loss of approximately $14.171 million a year earlier, based on $169.584 million of revenue and $167.804 million of costs and operating expenses.
- Operating cash flow turned positive
- Six-month operating cash flow improved to $17.7 million provided, from $37.2 million used in the prior-year period, supported by a $115.1 million increase in net product sales.
- Liquidity and working capital strengthened
- Liquidity increased materially at quarter end: cash and equivalents were $117.735 million and marketable debt securities were $371.442 million, producing $463.116 million of net working capital and a 4.05 current ratio.
- Peg tibatinase program restarted after pause
- Management restarted HARMONY enrollment in Q1 2026 and dosed the first new patient in April 2026 after manufacturing process improvements; topline pegtibatinase data are anticipated in 2H 2027.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Convertible-note transaction drove EPS loss
- Diluted GAAP EPS was a loss of $0.37, versus a $0.14 loss in Q2 2025, principally because the partial 2029-note repurchase produced a $40.008 million inducement expense. This masked otherwise positive operating performance.
- Higher launch and pipeline costs pressure earnings
- Commercial and development spending rose sharply: SG&A increased $33.531 million year over year to $96.112 million for FILSPARI IgAN investment and the FSGS launch, while R&D increased $10.921 million to $60.283 million, including a $10.961 million increase in pegtibatinase external costs.
- Commercial, generic and supply risks remain material
- The updated risk factors identify commercial execution, supply-chain and policy risks around FILSPARI. Tiopronin sales already fell $2.681 million year over year to $20.274 million amid generic competition, while FILSPARI relies on third-party manufacturing and carries Ligand royalties of 15% to 17% of net sales.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.37
- Gross margin
- 98.7%
- Operating margin
- 1.0%
- Segment
- FILSPARI net product sales: $141.078 million, up $69.191 million year over year from $71.887 million
- Segment
- Tiopronin products net sales: $20.274 million, down $2.681 million year over year from $22.955 million
- Segment
- License and collaboration revenue: $8.232 million, down $11.375 million year over year from $19.607 million
What they said about what is next.
No numeric revenue or EPS guidance was provided in the 10-Q. Management anticipates pegtibatinase Phase 3 HARMONY topline data in the second half of 2027 and believes cash plus short-term investments and anticipated operating cash generation will fund operations beyond the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 4, 2026
- Travere Therapeutics reported total revenue of $127.2 million for Q1 2026, up 45.5% year-over-year, bolstered by a notable increase in FILSPARI sales, which rose 88% to $105.2 million. The company reported positive EPS…
- 10-K · February 19, 2026
- Travere showed strong commercial and milestone-driven revenue growth in 2025 (quarterly sales of $82M, $114M, $165M and $130M), driven by FILSPARI approvals and partnership milestones, but Q4 2025 operating performance…
- 10-Q · October 30, 2025
- Travere reported a strong operational quarter: revenue of $164,859,000 (Q3 2025) vs $62,898,000 a year earlier and operating income of $24,931,000 versus an operating loss of $(56,149,000) in Q3 2024. Diluted EPS was…
- 10-K · February 21, 2025
- Travere secured full FDA approval for FILSPARI (sparsentan) on September 5, 2024, supported by PROTECT results showing a statistically significant treatment effect on eGFR (1.2 mL/min/1.73 m2/year; p=0.0168). Commercial…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TVTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever